All News
Askanase et al. Phase 2 RCT Cenerimod (S1P modulator) in SLE. Primary endpoint not met. Some suggestion of efficacy at highest 4mg dose. But if its already like this in a phase 2, I doubt a phase 3 will bring better results @RheumNow #ACR22 Abstr#1656 https://t.co/p4fcKW3cYD https://t.co/ha8xqeW6Xk
Richard Conway RichardPAConway ( View Tweet)
@RheumNow Assessing CV events in hierarchical order (each level has additional CV event). Hypothesis that increased CV events are driven by VTE in all-comers with the 10mg dose. https://t.co/IfRdJBERuA
Julian Segan JulianSegan ( View Tweet)
L06 #ACR22 ORAL Surveillance Updates!
Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi
But, MACE numerically higher with Tofa w/ h/o ASCVD
Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk
Most important risk is pt's individual risks
@RheumNow https://t.co/jPPX7f5GRE
Eric Dein ericdeinmd ( View Tweet)
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA:
❗Pre-conceptional NSAID use
❗Age
Thought-provoking.
Time to re-evaluate our NSAID prescribing practices for ♀️ SpA?
#ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila RHEUMarampa ( View Tweet)
This single ctr retro cohort study by Dr ZKazmi showed ⬇️HPV vax rates & ⬆️HPV infxn rates
🔅In HPV+ pts, risk of persistent HPV infxn was similar among ♀️ aged 21-26y & 27-45y (p>0.05)
Is it time for updated cervical ca screening guidelines for #lupus?
#ACR22 @RheumNow ABST#1671 https://t.co/7Nh62EYc6Y
sheila RHEUMarampa ( View Tweet)
Interesting study (MAGICA) of withdrawing TCZ in GCA after 1 year of therapy
Comparing abrupt vs gradual discontinuation
Very important clinical quesiton; kudos to FVSG for making this happen!
#ACR22 #Vasculitis22 @RheumNow https://t.co/912GCFik6L
Mike Putman EBRheum ( View Tweet)
McCarter et al. RA patients intiating ICI. 46% risk of flare, happens quickly (27% in first 28 days) and then plateaus. Seropositive higher risk HR 1.95. No difference in mortality. @RheumNow #ACR22 Abstr#1667 https://t.co/o9SKdNAYcE https://t.co/FmN89LAggG
Richard Conway RichardPAConway ( View Tweet)
Ab1671 #ACR22 Cervical Cancer screening in SLE
106 SLE patients, mean age 40. Only 3.7% w HPV vax!
24% abnml PAP, 30% HPV infection
HPV highest in 21-26 yo (83%) vs 27-45 (35%)
ASCUS 50% HPV+, 1 pt squamous cell ca
Recs: HPV Vax💉, test HPV as high positivity
@RheumNow @KDAO2011 https://t.co/nHlvGVVm40
Eric Dein ericdeinmd ( View Tweet)
Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks.
@RheumNow #ACR22 #LateBreaking
Julian Segan JulianSegan ( View Tweet)
Peresolimab PD-1 agonist in RA Phase 2 RCT
Primary endpoint met w/ > improvement DAS28CRP Wk12
Also greater improvement of CDAI in both treated grps
TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg
https://t.co/QtclWIWAw9
Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
Aurelie Najm AurelieRheumo ( View Tweet)
Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h
Richard Conway RichardPAConway ( View Tweet)
Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY
Richard Conway RichardPAConway ( View Tweet)
Important late breaker re:barriers to MTX post Roe decision
6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists
This number should be 0%!!
#ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25
Mike Putman EBRheum ( View Tweet)
Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis
#ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC
sheila RHEUMarampa ( View Tweet)
Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
Richard Conway RichardPAConway ( View Tweet)
"FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 10 years" - Dr. M Humphrey Dr. B Humphrey #ACR22 #Osteoporosis Guidelines Session @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Adami et al. GCs as low as 2.5mg/day assoc bone loss in RMD. Preventable with anti-resporptives. GC>=5mg/day aHR 2.37 for fracture @RheumNow #ACR22 Abstr#L01 https://t.co/1Q8dDarcAB https://t.co/dW4glkerAL
Richard Conway RichardPAConway ( View Tweet)
Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
Richard Conway RichardPAConway ( View Tweet)
#ACR22 #Osteoporosis Guidelines Case Example:
The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow https://t.co/wF8LP0iZjw
TheDaoIndex KDAO2011 ( View Tweet)
Steroid-sparing in PMR: methotrexate most used, but what is the evidence?
Christian Dejaco says: variable at best.
We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
David Liew drdavidliew ( View Tweet)